Head-To-Head Review: Ainos (OTCMKTS:AIMD) versus Nova Eye Medical (OTCMKTS:ELXMF)

Profitability

This table compares Ainos and Nova Eye Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ainos	-515.80%	-44.32%	-40.35%
Nova Eye Medical	N/A	N/A	N/A

Valuation & Earnings

This table compares Ainos and Nova Eye Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$40,633.00	149.86	-$14.01 million	($2.55)	-0.17
Nova Eye Medical	N/A	N/A	N/A	$0.01	13.70

Nova Eye Medical has lower revenue, but higher earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than Nova Eye Medical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

0.3% of Ainos shares are owned by institutional investors. Comparatively, 12.4% of Nova Eye Medical shares are owned by institutional investors. 10.4% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Nova Eye Medical beats Ainos on 6 of the 8 factors compared between the two stocks.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

About Nova Eye Medical

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It offers iTrack, a glaucoma surgical device to reduce intraocular pressure in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.